Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Symptoms and General Pathology

Nervous System Diseases

Carcinoma, Non-Small-Cell Lung

Neoplasm Metastasis

Carcinoma

Lung Neoplasms

Brain Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Carcinoma, Bronchogenic

Bronchial Neoplasms

Neoplastic Processes

Central Nervous System Neoplasms

Nervous System Neoplasms

Brain Diseases

Central Nervous System Diseases

Antineoplastic Agents

All Drugs and Chemicals

Amino Acids

Gefitinib

Tyrosine Kinase Inhibitors

Protein Kinase Inhibitors

Enzyme Inhibitors

Tyrosine

Iressa (Gefitinib)

Lucio Crino, MD

The aim of the study is to determine if Iressa is effective in the treatment of Brain metastases from NCSLC

Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer

A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy

AstraZeneca

Digestive System Diseases

Colorectal Neoplasms

Intestinal Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Colonic Diseases

Intestinal Diseases

Rectal Diseases

Micronutrients

Hematinics

Vitamins

Irinotecan

Leucovorin

Fluorouracil

Antimetabolites

Immunosuppressive Agents

Immunologic Factors

Topoisomerase I Inhibitors

Antidotes

Protective Agents

Folic Acid

Vitamin B Complex

Trace Elements

Folate

Vitamin B9

5Fluorouracil

AstraZeneca Italy Medical Director, MD

The aim of the study is to determine if Iressa added to chemotherapy with Irinotecan, 5Fluorouracil and Leucovorin can prolong the period of time without any disease worsening (Time to Progression) in patients with metastatic colorectal cancer.

Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer

A Randomised, Non-Comparative, Multicentre, Phase II, Parallel-Group Trial Of ZD1839 (Iressa™) In Combination With 5 Fluorouracil, Leucovorin And Cpt-11 (Irinotecan) In Patients With Metastatic Colorectal Cancer

Carcinoma, Squamous Cell

Squamous Cell Carcinoma of Head and Neck

Head and Neck Neoplasms

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Neoplasms, Squamous Cell

Radiotherapy

The aim of the study is to determine if Iressa added to radiotherapy is effective and safe in shrinking tumour dimensions.

Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck

A 2 Part Phase 2 Trial to Evaluate ZD1839 (Iressa™) & Radiotherapy in Patients w/Locally Advanced Inoperable Squamous Cell Carcinoma of the Head & Neck

Cisplatin

postoperative chemoradiotherapy with cisplatin

postoperative chemoradiotherapy with cisplatin + gefitinib

chemoradiotherapy with cisplatin

Rene-Jean Bensadoun, MD

This trial will be an open multicentric randomized phase II study comparing post-operative radiotherapy + cisplatin associated or not with Iressa in upper aerodigestive tract carcinomas.

Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas

CARISSA Trial - Multicenter Randomized Phase II Trial Comparing Post-operative Radiotherapy and Cisplatin Alone or in Combination With the EGFR Inhibitor ZD 1839 (Iressa) in Upper Aerodigestive Tract Carcinomas

Groupe Oncologie Radiotherapie Tete et Cou

The aim of the study if to determine if Iressa can prolong the period of time without any disease worsening (Time to progression) in patients previously treated with combined therapy such as surgery and chemotherapy with or without radiotherapy or chemotherapy and radiotherapy

Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC

A Phase III, Double-Blind, Randomised Study Comparing ZD1839 (IressaTM) Versus Placebo As Maintenance Therapy In Subjects With Locally Advanced Stage III Non-Small Cell Lung Cancer (NSCLC) After Combined Modality Therapy

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer	NCT00234442	Brain Neoplasms Non Small Cell ...	Iressa (Gefitin...	18 Years -	AstraZeneca
Irinotecan, 5-Fluorouracil and Leucovorin With or Without Iressa in the Treatment of Metastatic Colorectal Cancer	NCT00233623	Metastatic Colo...	Iressa (Gefitin... Irinotecan 5Fluorouracil Leucovorin	18 Years -	AstraZeneca
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck	NCT00233636	Head and Neck C... Carcinoma, Squa...	Iressa (Gefitin... Radiotherapy	18 Years -	AstraZeneca
Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer	NCT00234442	Brain Neoplasms Non Small Cell ...	Iressa (Gefitin...	18 Years -	AstraZeneca
Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper Aerodigestive Tract Carcinomas	NCT00169221	Head and Neck C...	Iressa (Gefitin... chemoradiothera...	18 Years -	Groupe Oncologie Radiotherapie Tete et Cou
Iressa and Radiotherapy in the Treatment of the Locally Advanced Inoperable Squamous Cell Carcinoma of the Head and Neck	NCT00233636	Head and Neck C... Carcinoma, Squa...	Iressa (Gefitin... Radiotherapy	18 Years -	AstraZeneca
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC	NCT00234468	Non Small Cell ...	Iressa (Gefitin...	18 Years -	AstraZeneca
Iressa vs Placebo as Maintenance Therapy in Locally Advanced NSCLC	NCT00234468	Non Small Cell ...	Iressa (Gefitin...	18 Years -	AstraZeneca

Spots Global Cancer Trial Database for iressa (gefitinib)